ID   KOWA
AC   CVCL_ZQ39
DR   Wikidata; Q98126832
RX   PubMed=1814424;
RX   PubMed=2778352;
RX   PubMed=7905727;
RX   PubMed=8596539;
RX   PubMed=9580660;
CC   Population: Japanese.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   22Y
CA   Finite cell line
DT   Created: 02-07-20; Last updated: 29-06-23; Version: 5
//
RX   PubMed=1814424;
RA   Nishigori C., Fujisawa H., Uyeno K., Kawaguchi T., Takebe H.;
RT   "Xeroderma pigmentosum patients belonging to complementation group F
RT   and efficient liquid-holding recovery of ultraviolet damage.";
RL   Photodermatol. Photoimmunol. Photomed. 8:146-150(1991).
//
RX   PubMed=2778352; DOI=10.1111/1523-1747.ep12284060;
RA   Nishigori C., Miyachi Y., Imamura S., Takebe H.;
RT   "Reduced superoxide dismutase activity in xeroderma pigmentosum
RT   fibroblasts.";
RL   J. Invest. Dermatol. 93:506-510(1989).
//
RX   PubMed=7905727; DOI=10.1001/archderm.1994.01690020057009;
RA   Nishigori C., Moriwaki S., Takebe H., Tanaka T., Imamura S.;
RT   "Gene alterations and clinical characteristics of xeroderma
RT   pigmentosum group A patients in Japan.";
RL   Arch. Dermatol. 130:191-197(1994).
//
RX   PubMed=8596539; DOI=10.1016/0921-8777(95)00052-6;
RA   Sato M., Nishigori C., Yagi T., Takebe H.;
RT   "Aberrant splicing and truncated-protein expression due to a newly
RT   identified XPA gene mutation.";
RL   Mutat. Res. 362:199-208(1996).
//
RX   PubMed=9580660; DOI=10.1093/hmg/7.6.969;
RA   Matsumura Y., Nishigori C., Yagi T., Imamura S., Takebe H.;
RT   "Characterization of molecular defects in xeroderma pigmentosum group
RT   F in relation to its clinically mild symptoms.";
RL   Hum. Mol. Genet. 7:969-974(1998).
//